CD47 and atherosclerosis: Studies in vitro showed that TSP-1 inhibits lymphangiogenesis via activation of CD47 in Lymphatic Endothelial Cells (LEC), which suggests that LEC CD47 could, in the future, be a potential therapeutic target in the treatment of atherosclerosis [15].